I think we'd be much farther along, especially the

I think we'd be much farther along, especially the GNBT litter of subsidiaries, than we are now. Spin out would have happened, Altucel would be in human trials, excellagen would be revenue positive positive etc etc. While the covid challenge opened up a chance at a bonanza, it also...just like the effect it has had on business in general...threw a monkey wrench into GNBT's plans.